Clinical Report: Exploring the Range of Tendon Toxicity Linked to Anastrozole
Overview
This study analyzes tendon disorders associated with third-generation aromatase inhibitors using data from the FDA’s FAERS database. Positive signals for tendon disorders were identified, highlighting the need for awareness of these potential adverse effects in clinical practice.
Background
Aromatase inhibitors are a cornerstone in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. Despite their efficacy, the risk of tendon disorders associated with these medications has often been underestimated. Understanding these risks is crucial for optimizing patient management and treatment outcomes.
Data Highlights
Drug
Onset Time (days)
Positive Signals
Letrozole
74
Trigger finger, Tenosynovitis stenosans
Exemestane
243.5
Trigger finger, Tenosynovitis stenosans
Key Findings
Positive signals for tendon disorders were identified for all three aromatase inhibitors.
Letrozole had the earliest onset of tendon disorders at 74 days.
Exemestane showed the latest onset of tendon disorders at 243.5 days.
Trigger finger and tenosynovitis stenosans presented significant signals.
A clear association between third-generation aromatase inhibitors and tendon disorders was observed after excluding combination drugs.
Clinical Implications
Healthcare professionals should be vigilant regarding the potential for tendon disorders in patients receiving third-generation aromatase inhibitors. Early recognition and management of these adverse effects may improve patient quality of life and treatment adherence.
Conclusion
The study highlights the varying degrees of tendon toxicity associated with third-generation aromatase inhibitors, emphasizing the importance of monitoring for these adverse effects in clinical practice.
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.
